

# Xiling Jiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12001240/publications.pdf>

Version: 2024-02-01

6  
papers

134  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

121  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. <i>MAbs</i> , 2018, 10, 876-889.	5.2	38
2	Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 291-304.	1.8	30
3	Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. <i>AAPS Journal</i> , 2016, 18, 767-776.	4.4	27
4	Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 140-155.	2.5	19
5	Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 146, 105260.	4.0	15
6	Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model. <i>Pharmaceutical Research</i> , 2016, 33, 1040-1049.	3.5	5